Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Revenues:        
License and collaborative fees $ 605 $ 2,525 $ 1,003 $ 3,538
Contract and other 6,336 6,181 15,133 15,026
Net product sales 210 569 469 576
Total revenues 7,151 9,275 16,605 19,140
Operating expenses:        
Research and development 17,049 18,441 33,640 34,211
Selling, general and administrative 4,081 3,567 8,203 8,246
Restructuring 79 676 97 4,453
Cost of sales 21 81 67 82
Total operating expenses 21,230 22,765 42,007 46,992
Loss from operations (14,079) (13,490) (25,402) (27,852)
Other income (expense):        
Interest expense (1,164) (1,025) (2,336) (2,068)
Other income (expense) (224) 542 224 (122)
Revaluation of contingent warrant liabilities (1,781) (2,182) (14,621) (16,538)
Net loss (17,248) (16,155) (42,135) (46,580)
Basic and diluted net loss per common stock (in dollars per share) $ (0.21) $ (0.24) $ (0.51) $ (0.83)
Shares used in computing basic and diluted net loss per share of common stock (in shares) 82,939 68,087 82,768 56,221
Other comprehensive loss:        
Net loss (17,248) (16,155) (42,135) (46,580)
Net unrealized gains on available-for-sale securities (11) 5 (8) 5
Comprehensive loss $ (17,259) $ (16,150) $ (42,143) $ (46,575)